Christopher D Soares

US Patent:

6479492, Nov 12, 2002

Filed:

Jan 21, 2000

Appl. No.:

09/489378

Inventors:

Andrei W. Konradi - San Francisco CA
Michael A. Pleiss - Sunnyvale CA
Eugene D. Thorsett - Half Moon Bay CA
Susan Ashwell - Plainsboro NJ
Dimitrios Sarantakis - Newtown PA
Gregory S. Welmaker - Jackson NJ
Anthony Kreft - Langhorne PA
Christopher Semko - Fremont CA
Robert Warren Sullivan - Oceanside CA
Christopher Joseph Soares - La Jolla CA
Kiev Sui Ly - San Diego CA
Christine M. Tarby - Hockessin DE

Assignee:

Elan Pharmaceuticals, Inc. - So. San Francisco CA

International Classification:

A61K 3153

US Classification:

514241, 514245, 544180, 544194, 544204, 544217, 544220

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimers disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

6903088, Jun 7, 2005

Filed:

Aug 15, 2002

Appl. No.:

10/218445

Inventors:

Andrei W. Konradi - San Francisco CA, US
Michael A. Pleiss - Sunnyvale CA, US
Eugene D. Thorsett - Half Moon Bay CA, US
Christopher Semko - Fremont CA, US
Robert Warren Sullivan - Oceanside CA, US
Christopher Joseph Soares - La Jolla CA, US
Kiev Sui Ly - San Diego CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA
Wyeth - Madison NJ

International Classification:

A61K031/33
A61K031/44
C07D213/02

US Classification:

514183, 514352, 514 1, 546304, 546307, 546329, 546345

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimer's disease, antherosclerosis. AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

7538215, May 26, 2009

Filed:

Jun 2, 2005

Appl. No.:

11/145489

Inventors:

Andrei W. Konradi - San Francisco CA, US
Michael A. Pleiss - Sunnyvale CA, US
Eugene D. Thorsett - Half Moon Bay CA, US
Christopher Semko - Fremont CA, US
Christopher Joseph Soares - La Jolla CA, US
Christine M. Tarby - Hockessin DE, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA
Wyeth - Madison NJ

International Classification:

C07D 239/02
C07D 237/00
C07D 415/00

US Classification:

544330, 544327, 544328, 544329, 544332

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.